Ligand Pharmaceuticals.
biopharmaceutical company based out of La Jolla, California
- Reports this week
- 0
- Active events
- 0
- Connections
- 53
What's happening
Earlier this month
-
Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.Some support4 reports2 developments inside
-
Ligand Pharmaceuticals committed funding and royalty rights to AvenCell Therapeutics, Inc.Some support1 report
One to three months ago
-
Director Jason Haas sold shares of Ligand Pharmaceuticals on September 13, 2026, which traded on the Nasdaq.Some support1 report
-
Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.Some support2 reports
-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
Ligand Pharmaceuticals funds drug development in partnership with Merck.Some support1 report
-
Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.Some support1 report
-
Analyst increased price target and rating for Ligand Pharmaceuticals.Some support1 report
-
Gibbs Wealth Management increased its holdings in Ligand Pharmaceuticals in Q1 and sold shares in July 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
Geode Capital Management increased its stake in Ligand Pharmaceuticals and filed required reports with the SEC.Some support1 report
-
Ligand Pharmaceuticals stock trades on Nasdaq, with Citigroup issuing buy ratings and a director selling shares.Some support2 reports
-
Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.Some support1 report
-
Ligand Pharmaceuticals stock trades on Nasdaq; Bank of America provides coverage and rating reports; required 13F reports are filed with the SEC.Some support1 report
-
Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.Speculative2 reports
-
Ligand Pharmaceuticals, based in La Jolla, CA, benefits from the current investment environment in the US market.Some support1 report
-
BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Ligand Pharmaceuticals this week
News at the entities that move Ligand Pharmaceuticals most-
FDA StructuralFDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.Moves Ligand Pharmaceuticals
-
Merck StructuralMerck is expanding its operations in Montgomery County.Moves Ligand Pharmaceuticals
-
Citigroup TransactionalTD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.Moves Ligand Pharmaceuticals
-
Pfizer OperationalStudy results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.Moves Ligand Pharmaceuticals
-
SEC StructuralLedjr AI acquired voting control of SPYR, which must now file a registration statement with the SEC and aims for a Nasdaq listing.Moves Ligand Pharmaceuticals
-
Merck KGaA OperationalNasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Moves Ligand Pharmaceuticals
Connections
The 21 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Ligand Pharmaceuticals is a company that lists and trades its stock on the Nasdaq exchange.
-
representative Transactional
Representative purchased shares of Ligand Pharmaceuticals.
-
Todd Davis Structural
Todd Davis holds the role of CEO for Ligand Pharmaceuticals.
-
Merck Structural
The companies are in a partnership where Merck funds Ligand's drug development and provides royalty revenue from its portfolio.
-
Pfizer Operational
Ligand Pharmaceuticals and Pfizer maintain ongoing partnerships for drug development and supply.
-
Citigroup Transactional
Citigroup has acted as a co-lead underwriter and provided investment ratings for Ligand Pharmaceuticals.
-
FDA Structural
The FDA provides formal regulatory approval necessary for Ligand Pharmaceuticals' drug products to enter the market.
-
Merck KGaA Operational
Ligand Pharmaceuticals and Merck KGaA maintain ongoing partnerships and alliances for drug development.
Show all 21 connections
-
Jason Haas Structural
Jason Haas holds a formal director role in Ligand Pharmaceuticals.
-
Amgen Operational
Ligand Pharmaceuticals and Amgen maintain an ongoing partnership for drug development.
-
SEC Structural
Ligand Pharmaceuticals is subject to formal disclosure and oversight requirements mandated by the SEC.
-
Securities and Exchange Commission Structural
Ligand Pharmaceuticals must file required 13F reports with the Securities and Exchange Commission.
-
LinkedIn Structural
Ligand Pharmaceuticals utilizes LinkedIn as a platform for investor relations and corporate disclosure.
-
Royal Bank of Canada Mentioned together
RBC issues target price and rating reports influencing market perception of Ligand Pharmaceuticals.
-
Geode Capital Management Transactional
Geode Capital Management increased its equity stake in Ligand Pharmaceuticals during the quarter.
-
Servier Structural
The relationship is functional, based on assets acquired via a specific XOMA Royalty deal.
-
Gil Cisneros Transactional
Gil Cisneros purchased shares of Ligand Pharmaceuticals.
-
Gildan Activewear Mentioned together
Both Gildan Activewear and Ligand Pharmaceuticals are noted as publicly traded companies.
-
Bank of America Mentioned together
Bank of America provides market coverage and rating reports for Ligand Pharmaceuticals.
-
Booking Holdings Mentioned together
No direct relationship or coupling between Booking Holdings and Ligand Pharmaceuticals was observed in the provided evidence.
-
Constellation Brands Mentioned together
Based on the evidence, no direct competitive link is mentioned between Constellation Brands and Ligand Pharmaceuticals.
History
Events by the month they beganSeptember 2026
3 events- Ligand Pharmaceuticals committed funding and royalty rights to AvenCell Therapeutics, Inc.
- Director Jason Haas sold shares of Ligand Pharmaceuticals on September 13, 2026, which traded on the Nasdaq.
- Ligand Pharmaceuticals received FDA approval for its drug Filspari and was listed on the Nasdaq stock exchange.
August 2026
3 eventsJuly 2026
2 eventsShow 1 earlier month
June 2026
8 events- Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Ligand Pharmaceuticals stock trades on Nasdaq, with Citigroup issuing buy ratings and a director selling shares.
- Ligand Pharmaceuticals trades on Nasdaq, receiving analyst upgrades from Citigroup and Bank of America.
- Ligand Pharmaceuticals stock trades on Nasdaq; Bank of America provides coverage and rating reports; required 13F reports are filed with the SEC.
- Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.
- Ligand Pharmaceuticals, based in La Jolla, CA, benefits from the current investment environment in the US market.
- BofA Securities and Citigroup served as co-lead underwriters for an offering involving Ligand Pharmaceuticals on August 22, 2025.